CTOs on the Move


 
AzoRx, Inc. is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.azorx.com
  • 4717 Campus Dr
    Kalamazoo, MI USA 49008
  • Phone: 269.760.0403

Executives

Name Title Contact Details

Similar Companies

Pharm A Save

Pharm A Save is a Monroe, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RareMed

RareMed Solutions offers comprehensive support services for specialty, orphan and ultra-orphan products. Our team has a breadth of experience developing and maintaining therapy specific solutions to ensure compliance. RareMed Solutions is the ideal partner for biotech firms and pharmaceutical manufacturers due to our custom solutions that are unique to each of our partner’s needs. RareMed Solutions is committed to providing the highest level of care to patients we serve. We offer specialized, highly-customizable services designed to increase patient access, affordability, and adherence to therapy. The extensive experience and unmatched service delivery translates to the best possible care for patients as well as enhancing product performance.

Hysitron

Hysitron is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.

Dyancon

Dyancon is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.